<DOC>
	<DOCNO>NCT03005717</DOCNO>
	<brief_summary>Study LIPO-202-CL-31 multi center , randomize , double-blind , placebo-controlled study evaluate safety efficacy two different dos LIPO-202 versus placebo submental bulging due subcutaneous fat . Approximately 150 participant either gender `` Moderate Bulge '' `` Large Bulge '' submental fat ( Patient-Reported Submental Bulging Scale [ PR-SBS ] Clinician-Reported Submental Bulging Scale [ CR-SBS ] ) recruit study .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy LIPO-202 Reduction Submental Subcutaneous Fat</brief_title>
	<detailed_description>Potential subject present complete Screening Visit . All qualify subject randomize one three treatment group treat 30 subcutaneous injection assign study drug submental fat , week 8 week . Upon completion treatment visit , subject return clinic follow-up visit end study visit , one four week last treatment . The number pattern injection base area ( cm x cm ) submental fat baseline . At visit subject also undergo examination treatment area , collection vital sign question possible adverse event ( AEs ) . The study consist 11 visit : Screening Visit , eight Treatment Visits , Follow Visit End Study Visit .</detailed_description>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Healthy male nonpregnant female ; 2 . Capable provide write , informed consent ; , 3 . Have submental bulging evaluate Investigator `` Moderate '' `` Large '' . 1 . History prior treatment reduce submental bulging ; 2 . History derm filler , chemical peel , laser radio frequency procedure neck/chin area within 12 month screen ; 3 . History botulinum toxin neck/chin area within 6 month screen ; 4 . Any skin condition ( include , limited : skin infection , psoriasis , eczema , keloid , tattoo hypertrophic tethered scar ) history trauma treatment area may affect study procedure ; 5 . A score 4 ( Extreme Laxity ) Skin Laxity Assessment Scale Visit 1 ( Screening ) ; 6 . Any known hypersensitivity study drug and/or component ; 7 . Prior current enrollment Lithera/Neothetics sponsor LIPO102/LIPO202 study ; 8 . Concurrently enrol another investigational drug device study use experimental investigational drug device within 30 day screen ; 9 . Female subject pregnant lactating ; 10 . Any medical condition opinion Investigator might complicate study procedure assessment jeopardize subject 's safety , include , limited : 1. bleed connective tissue disorder ; 2. clinically significant kidney liver disease ; 3. untreated thyroid disease ; 4. asthma , COPD , diabetes ( Type I II ) cardiovascular disease 5. history major surgery within 30 day prior randomization , plan surgery study period ; 11 . Used drug anticoagulant activity ( include aspirin ) within 14 day prior randomization , Î² adrenergic receptor agonist blocker , strong CYP3A inhibitor , nonpotassium spar diuretic ( e.g. , loop thiazide diuretic ) within 28 day prior randomization ; 12 . Used tricyclic antidepressant monoamine oxidase inhibitor medication within 14 day prior randomization ; 13 . Unlikely unable adhere study visit schedule comply protocol procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>submental</keyword>
	<keyword>Salmeterol Xinafoate</keyword>
	<keyword>LIPO-202</keyword>
	<keyword>bulge</keyword>
</DOC>